Author(s): Santana, Wanessa ; de Oliveira, Simone S. C. ; Ramos, Mariana H. ; Santos, André L. S. ; Dolabella, Silvio S. ; Souto, Eliana B. ; Severino, Patrícia ; Jain, Sona
Date: 2021
Persistent ID: https://hdl.handle.net/1822/74070
Origin: RepositóriUM - Universidade do Minho
Subject(s): Leishmaniasis; New targets; Pre-clinical; Clinical; Drug repurposing
Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (invitro, invivo), drug repurposing and clinical research.
